Shuqin Yu - Pharmacokinetics, Efficacy, and Safety Evaluation of Docetaxel/Hydroxypropyl-Sulfobutyl-beta-Cyclodextrin Inclusion Complex

Document created by Shuqin Yu on Aug 22, 2014
Version 1Show Document
  • View in full screen mode

  Publication Details (including relevant citation   information):

    Hydroxypropyl-sulfobutyl-β-cyclodextrin (HP-SBE-β-CD) inclusion   complex was developed and used as a drug delivery system for DTX   (DTX/HP-SBE-β-CD). The objective of the present study was to   evaluate and compare the biological properties of DTX/HP-SBE-Β-CD   with Taxotere®. The pharmacokinetics, biodistribution, antitumor   efficacy   in vivo   and   in vitro,   and safety evaluation of DTX/HP-SBE-β-CD were studied. The most   significant finding was that it was possible to prepare a   Polysorbate-80-free inclusion complex for DTX. Studies based on   pharmacokinetics, biodistribution, and antitumor efficacy   indicated that DTX/HP-SBE-β-CD had similar pharmacokinetic   properties and antitumor efficacy both   in vitro   andin   vivo   as Taxotere®. Fortunately, this new drug delivery system   attenuated the side effects when usedin   vivo.   As a consequence, DTX/HP-SBE-β-CD may be a promising alternative   to Taxotere® for cancer chemotherapy treatment with reduced side   effects. The therapeutic potential against a variety of human   tumors and low toxicity demonstrated in a stringent study clearly   warrant clinical investigation of DTX/HP-SBE-β-CD for possible   use against human tumors.


  Address (URL): http:///